Vincent Beliveau
Head of Data Infrastructure, Human Genome Austria
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Year:
2026
Year:
2026
Objectives To investigate trajectories of regional brain volume changes in multiple system atrophy (MSA) and their potential utility as surrogate markers of disease progression in the cerebellar subtype (MSA‐C). Background Reliable biomarkers for tracking disease progression in MSA are urgently needed. Although several studies have explored neuroimaging markers, imaging measures that are reliable and reproducible at the individual‐level are lacking. Methods Longitudinal three‐dimensional (3D)‐T1 images from multiple cohorts of 21 subjects with probable MSA‐C, 19 with probable MSA‐parkinsonian subtype (MSA‐P), 113 with Parkinson's disease, and 227 healthy controls were processed using the FreeSurfer longitudinal pipeline. Extracted volumes were assessed for individual longitudinal trajectories, intra‐individual variability, and pontine regional volume decline. Results Pontine volumes showed lower intra‐individual variability in measurements compared with other infratentorial brain regions. All probable MSA‐C patients exhibited a decline in pontine volume, ranging from −3.6% to −16.8% per year (mean: −9.1%), falling more than two standard deviations below the mean of healthy controls. In MSA‐C, the temporal dynamics of pontine volumes exhibited nonlinear changes, characterized by progressive atrophy in the earlier period of the disease, followed by a pre‐plateau phase associated with advanced disability in the later period. Predictive modeling suggests that pontine atrophy may begin before symptom onset of MSA‐C. Conclusions Pontine volume is a sensitive marker of disease progression, exhibiting a nonlinear decline with low intra‐individual variability in measurements and greater volume loss in the earlier stages, reaching a pre‐plateau phase in the later stages with advanced disability. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Year:
2025
Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiological mechanisms and impact of environmen-tal context remain unclear. Here, we tested whether a single dose of psilocybin alters synap-tic density in healthy individuals and whether setting-dependent subjective experience shapes this effect. Fifteen healthy participants had a psilocybin-induced psychedelic experi-ence either inside an MRI scanner or in a therapeutic-like room. We assessed synaptic densi-ty changes by measuring the Synaptic Vesicle glycoprotein 2A in the frontal cortex and hip-pocampus with [¹¹C]UCB-J PET at baseline and one-week post-dose, and assessed subjective experiences immediately afterwards and at three months. Participants treated in the thera-peutic-like setting exhibited more intense mystical-type experiences, longer-lasting psycho-logical benefits, and greater increases in synaptic density than those dosed in the MRI scan-ner. These findings indicate that psilocybin’s neuroplastic effects are modulated by envi-ronmental context, with important implications for psychedelic-assisted therapies.
Year:
2025
Neurotransmitter receptors guide the propagation of signals between brain regions. Mapping receptor distributions in the brain is therefore necessary for understanding how neurotransmitter systems mediate the link between brain structure and function. Normative receptor density can be estimated using group averages from Positron Emission Tomography (PET) imaging. However, the generalizability and reliability of group-average receptor maps depends on the inter-individual variability of receptor density, which is currently unknown. Here we collect group standard deviation brain maps of PET-estimated protein abundance for 12 different neurotransmitter receptors and transporters across 7 neurotransmitter systems, including dopamine, serotonin, acetylcholine, glutamate, GABA, cannabinoid, and opioid. We illustrate how cortical and subcortical inter-individual variability of receptor and transporter density varies across brain regions and across neurotransmitter systems. We complement inter-individual variability with inter-regional variability, and show that receptors that vary more across brain regions than across individuals also demonstrate greater out-of-sample spatial consistency. Altogether, this work quantifies how receptor systems vary in healthy individuals, and provides a means of assessing the generalizability of PET-derived receptor density quantification.
Year:
2025
Objective The objective of this study is to perform an independent assessment of the diagnostic utility of three state-of-the-art tools for the detection of focal cortical dysplasia (FCD) from Magnetic Resonance images (MRI). These tools include DeepFCD, the Multi-center Epilepsy Lesion Detection (MELD) Classifier, and the MELDGraph. Methods T1-weighted and fluid-attenuated inversion recovery MR images from 101 epilepsy patients with FCD and 101 age- and sex-matched epilepsy patients without FCD were included. Classifiers were evaluated at a patient-level by their ability to correctly identify the presence of any FCD lesions, and at a lesion-level by their capacity to identify lesions within the region delineated by the neuroradiologist in the MRI report. A calibrated threshold for DeepFCD prediction probabilities was empirically determined to improve classifier specificity. Test-retest consistency of the classifiers was measured using the Dice coefficient on repeated MRI scans of 21 individuals. Results For assessments at patient-level, high false positive rates were prominent, with the MELDClassifier achieving 52% accuracy (sensitivity=91%, specificity=14%). MELDGraph performed with accuracy up to 61% (sensitivity=76%, specificity=47%) and DeepFCD reached 56% accuracy (sensitivity=62%, specificity=50%) at an empirically determined threshold of 0.90. When investigating specific lesions, the MELDClassifier performed with a sensitivity of 91% and positive predictive value (PPV) of 13%, and MELDGraph performed with a sensitivity of 69% and PPV of 36%, whereas the DeepFCD achieved a sensitivity of 100% and PPV of 4%. Test-retest reliability was low, with an average [min, max] Dice coefficient of 0.28 [0.0, 1.0] for MELDClassifier, 0.38 [0.0, 1.0] for MELDGraph with harmonization and 0.35 [0.05, 0.54] for DeepFCD. Significance This study highlights the current limitations of using deep learning models in FCD diagnosis and emphasizes the need to enhance the tools’ accuracy, reliability, and interpretability to improve their clinical utility in epilepsy diagnosis. Key points - State-of-the-art deep learning tools for identifying focal cortical dysplasia perform with high sensitivity ranging from 69% to 100% - When predicting the presence of any lesion within epilepsy patients’ MRI scans, the classifiers performed with accuracies ranging from 52% to 61% - The average false positive count per patient ranged from 0.49 ± 0.66 (MELDGraph) to 32.71 ± 14.35 (DeepFCD). - All three classifiers had low test-retest consistency, suggesting that the predictions may be strongly influenced by the noise in the images.
Year:
2025
Synapses are fundamental to the function of the central nervous system and are implicated in a number of brain disorders. Despite their pivotal role, a comprehensive imaging resource detailing the distribution of synapses in the human brain has been lacking until now. Here, we employ high-resolution PET neuroimaging in healthy humans (17F/16M) to create a 3D atlas of the synaptic marker Synaptic Vesicle glycoprotein 2A (SV2A). Calibration to absolute density values (pmol/ml) was achieved by leveraging postmortem human brain autoradiography data. The atlas unveils distinctive cortical and subcortical gradients of synapse density that reflect functional topography and hierarchical order from core sensory to higher-order integrative areas—a distribution that diverges from SV2A mRNA patterns. Furthermore, we found a positive association between IQ and SV2A density in several higher-order cortical areas. This new resource will help advance our understanding of brain physiology and the pathogenesis of brain disorders, serving as a pivotal tool for future neuroscience research.
Year:
2024
Year:
2024
Background Subthalamic deep brain stimulation (STN‐DBS) reduces antiparkinsonian medications in Parkinson's disease (PD) compared with the preoperative state. Longitudinal and comparative studies on this effect are lacking. Objective To compare longitudinal trajectories of antiparkinsonian medication in STN‐DBS treated patients to non‐surgically treated control patients. Methods We collected retrospective information on antiparkinsonian medication from PD patients that underwent subthalamic DBS between 1999 and 2010 and control PD patients similar in age at onset and baseline, sex‐distribution, and comorbidities. Results In 74 DBS patients levodopa‐equivalent daily dose (LEDD) were reduced by 33.9–56.0% in relation to the preoperative baseline over the 14‐year observational period. In 61 control patients LEDDs increased over approximately 10 years, causing a significant divergence between groups. The largest difference amongst single drug‐classes was observed for dopamine agonists. Conclusion In PD patients, chronic STN‐DBS was associated with a lower LEDD compared with control patients over 14 years.
Year:
2024
Year:
2023
Year:
2023
Collaborators (23)
Lauri Nummenmaa
Professor
Turku PET Centre
Colm McGinnity
King’s College London
Lars H. Pinborg
-
Justine Hansen
McGill University
Maria Zofia Geisler
University of Southern Denmark
Hirohisa Watanabe
Professor and Chairman
Fujita Health University
Marco Leyton
Professor
McGill University
Nakul Raval
Associate Research Scientist
Yale University
Bratislav Misic
Associate Professor
McGill University
Gitte Moos Knudsen
Center director
Rigshospitalet
Patrick Fisher
Associate Professor
University of Copenhagen
Wassilios Meissner
University of Bordeaux
Jarmo Hietala
Toulouse University Hospital
Alexander Hammers
Head of PET Centre / Professor (Hon. Consultant) of Imaging and Neuroscience
King’s College London
Eliane Kobayashi
AssociateProfessor
William P. Clements Jr. University Hospital
Vibeke Høyrup Dam
Københavns Universitet
Jouni Tuisku
University of Turku
Kazuya Kawabata
Senior Assistant Professor
Fujita Health University
Susana Aznar
Head of Research
Bispebjerg Hospital
Melanie Ganz
Associate Professor
University of Copenhagen
Marian Galovic
Head of Epilepsy Unit, Consultant Neurologist
University of Zurich
PEDRO ROSA-NETO
Professor
McGill University
Paul Marsden
Professor
King's College London
Make your next move.
Prepare your application
Review drafts before you send them.